Noticias y vídeos - SCYNEXIS INC.

In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the...

JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024. SCY-247 is being developed to address...

SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analyses The clinical study reports for FURI, CARES and NATURE in refractory invasive fungal infections are on target for delivery to GSK in the first half of 2024 which would trigger a $10 million...

JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6 th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET. Guggenheim’s 6 th Annual Biotechnology Conference Format: Fireside chat and one-on-one meetings...

In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosis Combination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burden in lung and brain tissue compared to monotherapies JERSEY CITY, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and...

Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! PR Newswire NEW YORK, Jan. 8, 2024 NEW YORK , Jan. 8, 2024 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against SCYNEXIS, Inc. ("Scynexis" or "the Company") (NASDAQ: SCYX) and certain of its officers. Class Definition: This...

SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! PR Newswire NEW YORK, Jan. 7, 2024 NEW YORK , Jan. 7, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against SCYNEXIS, Inc. ("Scynexis" or "the Company") (NASDAQ: SCYX) and certain of its officers. Class...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX PR Newswire NEW YORK, Jan. 6, 2024 NEW YORK , Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether SCYNEXIS and certain of its officers and/or directors...

JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11 th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024. Poster...

SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit PR Newswire LOS ANGELES, Jan. 4, 2024 LOS ANGELES , Jan. 4, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against SCYNEXIS, Inc. ("Scynexis" or the "Company") (NASDAQ: SCYX). Class Period: March 31, 2023 – September 22, 2023 Lead Plaintiff Deadline: January 8, 2024 If you wish to serve as...

SCYNEXIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options PR Newswire NEW YORK, Jan. 4, 2024 If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . You may...

SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit PR Newswire BENSALEM, Pa., Jan. 3, 2024 BENSALEM, Pa. , Jan. 3, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against SCYNEXIS, Inc. ("Scynexis" or the "Company") (NASDAQ: SCYX ). Class Period: March 31, 2023 – September 22, 2023 Lead Plaintiff Deadline: January 8, 2024 Investors suffering...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX PR Newswire NEW YORK, Dec. 28, 2023 NEW YORK , Dec. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether SCYNEXIS and certain of its officers and/or...

SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit PR Newswire LOS ANGELES, Dec. 28, 2023 LOS ANGELES , Dec. 28, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against SCYNEXIS, Inc. ("Scynexis" or the "Company") (NASDAQ: SCYX ). Class Period: March 31, 2023 – September 22, 2023 Lead Plaintiff Deadline: January 8, 2024 If you are a shareholder...

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options PR Newswire NEW YORK, Dec. 28, 2023 If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext....

TOP RANKED ROSEN LAW FIRM Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX PR Newswire NEW YORK, Dec. 25, 2023 NEW YORK , Dec. 25, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September 22, 2023 , both dates inclusive (the "Class Period"), of the important January 8, 2024 lead plaintiff deadline. SO WHAT: If...

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options PR Newswire NEW YORK, Dec. 21, 2023 If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext....

SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit PR Newswire BENSALEM, Pa., Dec. 20, 2023 BENSALEM, Pa. , Dec. 20, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against SCYNEXIS, Inc. ("Scynexis" or the "Company") (NASDAQ: SCYX ). Class Period: March 31, 2023 – September 22, 2023 Lead Plaintiff Deadline: January 8, 2024 Investors suffering...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX PR Newswire NEW YORK, Dec. 18, 2023 NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether SCYNEXIS and certain of its officers and/or...

SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit PR Newswire LOS ANGELES, Dec. 15, 2023 LOS ANGELES , Dec. 15, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against SCYNEXIS, Inc. ("Scynexis" or the "Company") (NASDAQ: SCYX ). Class Period: March 31, 2023 – September 22, 2023 Lead Plaintiff Deadline: January 8, 2024 If you wish to serve...